Background. Modern approaches to the therapy of diabetes mellitus (DM) involve the assessment of the success of therapy and glycemic control by the glycated hemoglobin level. Recently, however, the assessment of glycemic variability (GV) has become of great importance. Previously, assessment of GV required continuous monitoring of glycemia. Currently, such a tool as a of glycemic variability diary (GVD) is available.
Description of case series. Five clinical cases of patients with decompensated DM2 are presented. All patients underwent an assessment of glycemic control according to GVD before and after changing therapy. GVD that makes it possible to assess the efficacy and safety of DM therapy, and glycemic variability is used as an independent risk factor for the development of severe hypoglycemic conditions, diabetic micro- and macroangiopathy [1].
Conclusion. GVD has proven to be effective and important in the outpatient setting. The improvement of carbohydrate metabolism compensation when switching to ultra-long-acting insulin degludec with an increase in the time spent in the target glycemic range, a decrease in glycemic variability has been clearly demonstrated.

Keywords: glycemic variability diary, time in target range, degludec, glycemic variability, type 2 diabetes mellitus